P3008 - Small Intestinal Bacterial Overgrowth Prevalence in Patients With Systemic Sclerosis

Jamie Bering, MD, Jacqueline Cai, MD, Francisco C. Ramirez, MD, FACG, Sarah Umar, MD
Mayo Clinic, Scottsdale, AZ

Introduction: Currently, there is a paucity of information regarding the prevalence of small intestinal bacterial overgrowth (SIBO) in patients with systemic sclerosis (SSc). SIBO occurs when the small bowel becomes colonized with the bacteria normally found in the colon and can cause a variety of gastrointestinal (GI) symptoms including bloating, nausea, abdominal pain, flatulence, and diarrhea. Several risk factors for developing SIBO have been identified including intestinal dysmotility, anatomic disorders, and gastric hypochlorhydria, among others. We hypothesized that patients with SSc would have a higher incidence of SIBO than patients who have similar symptoms without underlying SSc.

Methods: We performed a retrospective review of patients with and without SSc who underwent testing for SIBO between 2007-2017 (n=2545). SIBO was diagnosed either via carbohydrate breath testing or small bowel aspiration during esophagogastroduodenoscopy (EGD). Breath testing was considered positive for SIBO if the concentration of exhaled hydrogen demonstrated a rise to at least 20 parts per million. Small bowel aspirates obtained during EGD were sent for quantitative cultures. A positive culture was defined as bacterial growth of >10⁵ cfu/mL. Comparison was made between patients with SSc who tested positive for SIBO and patients without SSc who tested positive for SIBO. Other variables were also collected including demographic data, narcotic use, proton pump inhibitor use, and diagnosis of gastroparesis

Results: A total of 2545 patients were reviewed (Table 1). Forty-eight of 126 patients with SSc tested positive for SIBO and 342 of 2419 patients without SSc tested positive for SIBO (38.1% vs 14.1%, p= 0.0001). Patients with SSc also had a higher incidence of gastroparesis, proton-pump inhibitor use, and abdominal surgeries compared with patients without SSc (Table 1).

Discussion: This is one of the largest studies so far investigating SIBO in patients with SSc. We found that patients with SSc had a higher incidence of SIBO compared with patients who had similar GI symptoms without underlying SSc. This is likely related to the fact that patients with SSc often have multiple risk factors for SIBO compared with their non-SSc counterparts. Because a large majority of patients with SSc also have GI symptoms, clinicians should consider the diagnosis of SIBO and initiate testing early.


Disclosures:


Jamie Bering, MD, Jacqueline Cai, MD, Francisco C. Ramirez, MD, FACG, Sarah Umar, MD. P3008 - Small Intestinal Bacterial Overgrowth Prevalence in Patients With Systemic Sclerosis, ACG 2021 Annual Scientific Meeting Abstracts. Las Vegas, Nevada: American College of Gastroenterology.